Table 2 Effect of FBS and HSA on IC50 values for ruxolitinib-dependent K562, HEL and SET-2 cell viability.

From: Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models

IC50 (μM)

Cell type

10% FBS

80 μM HSA

8 μM HSA

0.8 μM HSA

0.08 μM HSA

no HSA

K562

>10

>10

>10

>10

>10

>10

HEL

4.7 ± 1.0

4.1 ± 0.8

3.1 ± 0.6

2.2 ± 0.5

1.7 ± 0.4

1.0 ± 0.3

SET-2

0.15 ± 0.04

0.10 ± 0.03

0.033 ± 0.005

0.032 ± 0.004

0.035 ± 0.008

0.033 ± 0.008

Back to article page